3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Dermatologic
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
103
Lymphoma, Large B-Cell, Diffuse
80
Leukemia, Myeloid, Acute
74
Multiple Myeloma
70
Breast Neoplasms
70
Lymphoma, Non-Hodgkin
62
Lymphoma
61
Leukemia, Lymphocytic, Chronic, B-Cell
53
Burkitt Lymphoma
52
Recurrence
51
Myelodysplastic Syndromes
50
Lymphoma, Follicular
50
Lymphoma, B-Cell
47
Leukemia
43
Triple Negative Breast Neoplasms
40
Lymphoma, Mantle-Cell
38
Neoplasms
37
Hodgkin Disease
34
Melanoma
33
Lymphoma, B-Cell, Marginal Zone
32
Hematologic Neoplasms
31
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
29
Neuroblastoma
28
Ovarian Neoplasms
26
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
22
Neoplasm Metastasis
22
Pancreatic Neoplasms
21
Leukemia, Biphenotypic, Acute
21
Sarcoma
18
Myeloproliferative Disorders
17
Interventions
Doxorubicin
3
pembrolizumab
2
pazopanib
2
Radiotherapy
2
Radiation
2
Ifosfamide
2
selinexor
1
peposertib
1
liposomal doxorubicin
1
avelumab
1
Specimen Handling
1
Quality of Life
1
Proton Therapy
1
Nivolumab
1
Magnetic Resonance Spectroscopy
1
Immune Checkpoint Inhibitors
1
Imatinib Mesylate
1
Histamine H2 Antagonists
1
Famotidine
1
Dactinomycin
1
Cyclophosphamide
1
Blood Specimen Collection
1
Biopsy
1
BO-112
1
Angptl4 protein, mouse
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Dermatofibrosarcoma
×
Cyclophosphamide
×
1 year
×
Clear all
NCT01046487
2026-03-13
PALANGI3
Centre Oscar Lambret
Phase 1
Completed
26 enrolled